FindTrial
Sign In

A case-control study of relationship between genotyping and severe cutaneous adverse reactions

A case-control study of relationship between HLA-B*5801 genotyping and allopurinol induced severe cutaneous adverse reactions

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-RCC-12002927
Enrollment
Unknown
Registered
2012-12-24
Start date
2011-12-16
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

severe cutaneous adverse reactions caused by allopurinol

Interventions

2:Nil

Sponsors

Institute of Clinical Pharmacology, Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Aged above 6 months, below 75 years old; Willing to participate in the clinical test and sign informed consent; The clinical doctor diagnosed with gout disease, gout arthritis, uric acid stones or high urineAcidemia, and the doctors prescription instructions to accept allopurinol for therapy and the patients have serve skin adverse reaction.

Exclusion criteria

Exclusion criteria: 1. Once received bone marrow transplant patients; 2. Cancer or after chemical treatment patients; 3. the patients with drug of off-label using.

Design outcomes

Primary

MeasureTime frame
Genotype;—

Countries

China

Contacts

Public ContactWei Zhang
Yjsd2003@163.com+86 13973168774

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026